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Abstract
Colorectal cancer (CRC) accounts for high mortality. So far, there is lack of 
markers capable of predicting which patients are at risk of aggressive course of 
the disease. Protein phosphatase- 2A (PP2A) inhibitor proteins have recently 
gained interest as markers of more aggressive disease in certain cancers. Here, 
we report the role of PP2A inhibitor PME- 1 in CRC. PME- 1 expression was 
assessed from a rectal cancer patient cohort by immunohistochemistry, and 
correlations were performed for various clinicopathological variables and patient 
survival. Rectal cancer patients with higher cytoplasmic PME- 1 protein expres-
sion (above  median) had less recurrences (P = 0.003, n = 195) and better 
disease- free survival (DFS) than the patients with low cytoplasmic PME- 1 protein 
expression (below median). Analysis of PPME-1 mRNA expression from TCGA 
dataset of colon and rectal adenocarcinoma (COADREAD) patient cohort con-
firmed high PPME1 expression as an independent protective factor predicting 
favorable overall survival (OS) (P = 0.005, n = 396) compared to patients with 
low PPME1 expression. CRC cell lines were used to study the effect of PME- 1 
knockdown by siRNA on cell survival. Contrary to other cancer types, PME- 1 
inhibition in CRC cell lines did not reduce the viability of cells or the expres-
sion of active phosphorylated AKT and ERK proteins. In conclusion, PME- 1 
expression predicts for a favorable outcome of CRC patients. The unexpected 
role of PME- 1 in CRC in contrast with the oncogenic role of PP2A inhibitor 
proteins in other malignancies warrants further studies of cancer- specific func-
tion for each of these proteins.
Introduction
Colorectal cancer (CRC) is the third most common ma-
lignant neoplasm in many countries of the western world 
[1]. Its prognosis has improved gradually as a result of 
advancements in surgery and adjuvant chemotherapy [2]. 
However, a significant proportion of the patients still die 
of the disease [3]. There is a need for biomarkers to 
predict which patients are at risk of disease recurrence. 
This would help to direct adjuvant treatments to those 
patients that gain benefit from them and protect the low- 
risk patients from the side effects of therapy.
Protein phosphatase- 2A (PP2A) is a human tumor sup-
pressor, which protects against cellular transformation. It 
is the major serine–threonine phosphatase, which functions 
by negatively regulating the activity of numerous signaling 
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proteins important for malignant neoplasms [4–6]. 
Consequently, the neoplasms have developed various 
mechanisms to oppose the PP2A activity [5, 7]. Among 
these, three important endogenous PP2A inhibitors have 
been found: CIP2A, SET, and PME- 1 [5, 7–9]. 
Overexpression of CIP2A on protein level has been found 
in many human neoplasms, and it is a marker of poor 
outcome in several malignant neoplasms including CRC 
[10, 11]. SET in turn seems to be particularly important 
in hematological malignancies [12]. PME- 1 expression has 
been studied in only a limited number of human neo-
plasms, such as astrocytic gliomas, and endometrial, lung, 
and gastric cancers [9, 13, 14]. Elevated amounts of PME- 1 
have been found in endometrial and glial tumors, which 
are linked to the altered ERK pathway signaling, cell pro-
liferation, and disease progression of gliomas to malignant 
subtypes [9, 13]. Additionally, a small fraction (3–4%) 
of the gastric and lung cancer patients shows PPME1 
gene amplification, which also corresponds to elevated 
PME- 1 protein expression and activation of ERK and AKT 
survival signaling [14]. These studies have highlighted 
potential oncogenic role of PME- 1 in these malignant 
neoplasms. However, whether oncogenic function of PME- 1 
can be generalized to various human cancer types is as 
yet unclear. Also, the studies so far have failed to identify 
any correlation between tumor PME- 1 expression and the 
patient survival.
In this study, we report the immunohistochemical 
analysis of PME- 1 protein expression in the tumor mate-
rial of a rectal cancer patient cohort, and its correlation 
to the clinicopathological parameters as well as patient 
survival. Unexpectedly, in strike contrast with its previ-
ously shown oncogenic role in other malignancies, we 
show that high PME- 1 expression correlates with superior 
clinical outcome in CRC. The association of high PME- 1 
expression with better patient survival is confirmed at 
the mRNA level by using an independent CRC dataset. 
Finally, consistent with unexpected role for PME- 1 in 
CRC, PME- 1 inhibition in two human colon cancer cell 
lines fails to show any inhibitory effect on either cell 
survival or expression of phosphorylated AKT or ERK, 
shown to be regulated by PME- 1 in other previously 
studied cancer types.
Materials and Methods
Cell culture and siRNA transfections
Human colon carcinoma cell lines HCA- 7 and CW- 2 
(gifted by Prof. Olli Carpén, University of Turku) were 
cultured in DMEM (Sigma- Aldrich, Finland Oy, Helsinki, 
Finland) and RPMI (Sigma- Aldrich) media, respectively, 
supplemented with 10% heat- inactivated FBS (Gibco, 
Thermo Fisher Scientific Inc.,  Rockford, IL, USA), 
2 mmol/L l- glutamine, and penicillin (50 units/mL)–strep-
tomycin (50 μg/mL) in a humidified atmosphere of 5% 
CO2 at 37°C.
Small interfering RNA (siRNA) transfections were per-
formed with Lipofectamine RNAiMAX reagent (Invitrogen, 
Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions with the final siRNA concen-
tration of 50 nmol/L per well. The scrambled (Scr) or 
control (5′- GUA ACA AUG AGA GCA CGG C- 3′) and 
PME- 1- specific (5′- GGA AGU GAG UCU AUA AGC A- 
3′) siRNAs were purchased from Eurofins MWG Synthesis 
GmbH, Germany. Three days after transfections, cells were 
harvested for analysis.
Western blotting
Cells were lysed in 2× SDS sample buffer/Laemmli 
Buffer, boiled, and resolved by SDS- PAGE. Proteins 
were transferred to PVDF membranes (Millipore, Merck 
KGaA, Darmstadt, Germany), which were blocked and 
incubated with required dilution of primary (at +4°C, 
incubated overnight) and 1:5000 dilution of secondary 
antibody (at room temperature, for 1 h) in 5% milk- 
TBS- Tween- 20, and developed by enhanced chemilu-
minescence (Pierce Biotechnology, Rockford, IL, USA). 
PME- 1, clone B- 12 (sc- 25278) antibody used at 1:1000 
dilution, and phosphorylated AKT- 1/2/3 (Thr308) (sc- 
16646) antibody used at 1:500 dilution were purchased 
from Santa Cruz Biotechnology Inc., Dallas, TX, USA. 
Antibody for phosphorylated ERK- 1/2 (Thr202/Tyr204) 
(#4370) used at 1:1000 dilution was purchased from 
Cell Signalling Technology, Danvers, MA, USA. Loading 
control antibody for GAPDH (5G4- 6C5) (1:200,000 
dilution) was from HyTest Ltd., Turku, Finland. 
Densitometric analysis of the blots was performed using 
Image Lab software (Bio-Rad Laboratories Inc., Hercules, 
CA, USA).
Immunofluorescence
Cells were seeded on glass coverslips and transfected with 
siRNA. After 3 days, cells were fixed with 4% paraform-
aldehyde (Sigma- Aldrich) and permeabilized with 0.5% 
Triton X- 100 (Sigma- Aldrich) at room temperature for 
10 and 5 min, respectively. Immunostainings were carried 
out with anti- PME- 1 antibody (clone B- 12, sc- 25278) at 
1:50 dilution in 10% goat serum blocking buffer, overnight 
at +4°C under constant rocking. Negative control coverslips 
were incubated with blocking buffer alone (without PME- 1 
antibody). After 2–3 washes with PBS, coverslips were 
incubated with Alexa- 594- conjugated goat anti- mouse 
secondary antibody (A- 11005; Invitrogen, Life Technologies 
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Ltd, Paisley, UK) for 1 h at room temperature. Nuclei 
were stained with Hoechst 33342 (Invitrogen), 1:2000 
dilution in PBS for 10 min. Coverslips were mounted on 
glass slides over a drop of Mowiol (Sigma- Aldrich), and 
images were acquired with AxioVert 200M fluorescence 
microscope (Carl- Zeiss Microscopy GmbH, Göttingen, 
Germany) using 40× objective. Merged images were gen-
erated with ImageJ [15] (National Institutes of Health, 
Bethesda, MD).
Cell viability assays
Cell viability was determined by two different assays; 
CellTiter- glo (CTG) (Promega Corp., Madison, WI, USA) 
and cell proliferation reagent WST- 1 (Roche Diagnostics 
GmbH, Mannheim, Germany). CTG assay measures the 
cellular ATP levels as an indicator of metabolically active 
and viable cells. WST- 1 assay is dependent on NAD(P)
H production by glycolysis and the activity of mitochon-
drial dehydrogenase enzymes, an indicator of metabolically 
active viable cells. Both the assays were performed as per 
the manufacturer’s recommendations. CTG assay was per-
formed in polystyrene 96- well plates (Nunc, Thermo Fisher 
Scientific Inc., Paisley, UK) and luminescence was measured 
with Synergy H1 hybrid plate-reader (BioTek, Winooski, 
VT, USA). The WST- 1 assay was performed in clear bot-
tom 96- well plates and the absorbance was measured at 
450 nm.
Tumor samples
Formalin- fixed, paraffin- embedded tumor samples were 
collected from patients treated for rectal cancer at Turku 
University Central Hospital between 2000 and 2009. These 
included operative samples (n = 210) with tumors of the 
middle and lower rectum from the archives of the 
Department of Pathology, Turku University Hospital. 
Superficial tumors operated by local excision were excluded 
from the study as well as patients with distant metastases 
at the time of diagnosis. The permission for using the 
archival tissue material was granted by the National 
Supervisory Authority for Welfare and Health, Finland 
(permission # Dnro 1709/32/300/02, 13 May 2002).
For tumor staging, we applied the sixth edition of 
TNM classification of malignant tumors in use at the 
time the patients were operated [16]. Treatment was 
chosen according to preoperative tumor staging, includ-
ing computerized tomography (CT) or magnetic reso-
nance imaging (MRI) of the rectum, CT of the abdomen, 
and X- ray or CT of the chest. Patients were treated 
either with short- course preoperative radiotherapy (RT) 
(n = 88), long- course preoperative (chemo) RT (n = 52), 
or received no treatment before surgery (n = 70) on 
the basis of common clinical recommendations [17]. 
Short- course RT was given 5 Gy fractions on 5 days, 
and the patients were operated on the following week. 
Long- course RT was delivered in 1.8 Gy fractions to a 
total dose of 50.4 Gy in 6 weeks with (n = 43) or 
without (n = 9) chemotherapy. At that period, patients 
were operated 5–7 weeks after RT. The cytostatic treat-
ment included either bolus 5- fluorouracil (n = 4) or 
capecitabine (n = 39). The type of surgery was anterior 
resection among 113 (54%), and abdomino- perineal re-
section among 93 (44%) patients. Four (2%) patients 
were operated with low Hartmann’s procedure or other 
type of surgery. The majority of the specimens (n = 154) 
were screened to detect vascular invasion, which was 
found in 44 (28.6%) samples. Patients with established 
high- risk features were treated with adjuvant chemo-
therapy. The median follow- up time was 62.5 months. 
Disease recurrence was observed among 65 (31%) patients, 
either local or distant one. The clinical information of 
the patients is shown in Table 1.
Immunohistochemistry
Four of the 210 patients had no viable cancer cells left 
after preoperative treatment, classified as pT0. The amount 
of cancer cells was too scarce for a reliable evaluation of 
immunohistochemical staining in additional 11 patients. 
Consequently, samples of 195 patients were included in 
the final analysis. The most optimal paraffin blocks were 
selected to get enough tumor material for analyses. Sections 
of 5 μm were cut. The antigen retrieval was performed 
with microwave oven twice for 7 min in 10 mmol/L so-
dium citrate buffer, pH 9. For immunohistochemical 
staining, monoclonal mouse- anti- human PME- 1 (clone 
B12) antibody epitope corresponding to amino acids 
161–386 of PME- 1 of human origin (Santa Cruz 
Biotechnology, sc- 25278), at a dilution of 1:200 was used. 
For detection, the EnVisionTM + Dual Link System- HRP 
(Dako, Glostrup, Denmark) was utilized.
Analysis of PME- 1 expression
Two observes blinded to the clinical data evaluated the 
cytoplasmic and nuclear IHC staining of PME- 1 (A.E. 
all samples and E.M.B. 40 samples). Tissue from human 
glioblastoma was used as positive control. Both nuclear 
and cytoplasmic staining was scored on a scale of four 
intensity levels (+++, ++, +, −). The strong staining 
intensity (+++) corresponds to the positive control of 
PME- 1; weak staining intensity can still be distinguished 
from the background. Moderate staining intensity is 
intermediate between the previous ones. After estimating 
the predominant cytoplasmic and nuclear staining 
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intensities, staining indices were analyzed. These include 
the most intensive cytoplasmic and nuclear indices. To 
calculate these indices, the area of the most intensive 
staining in cancer cells was chosen from each sample. 
After that, the fractions of cancer cells belonging to 
each staining intensity categories were estimated. The 
following formula was used to calculate the staining 
indices: I = 0*f0 + 1*f1 + 2*f2 + 3*f3, where I is the 
staining index and f0–f3 are the fractions of the cells 
showing a defined level of staining (from 0 to 3). 
Theoretically, the index can vary between 0 and 3 [18].
Evaluation of the tumor regression grade
Tumor regression grade (TRG) after long- course RT was 
estimated by a pathologist (J.S.), using a scale of poor, 
moderate, or excellent TRG, according to a modified 
Dworak scale, as described previously [19]. Briefly, poor 
TRG was defined as minimal or no tumor regression 
after (chemo) RT. In case of poor response, a consider-
able amount of tumor cells were still remaining after 
treatment. In tumors with moderate response, there were 
only some tumor cells or tumor cell groups left in the 
Table 1. The clinical characteristics of the rectal cancer patients.
Total n = 210
Short- course radiotherapy,  
n (%)
Long- course radiotherapy,  
n (%)
Control,  
n (%)
Sex
 Male 119 54 (45) 32 (27) 33 (28)
 Female 91 34 (37) 20 (22) 37 (41)
Mean age (years) 65 64 74
Preoperative T1
 T1–2 48 27 (56) 0 (0) 21 (44)
 T3 68 54 (79) 2 (3) 12 (18)
 T4 49 1 (2) 45 (92) 3 (6)
 Tx 45 6 (13) 5 (11) 34 (76)
Postoperative T1,2
 T1 10 3 (30) 2 (20) 5 (50)
 T2 65 32 (49) 7 (11) 26 (40)
 T3 111 49 (44) 26 (24) 36 (32)
 T4 20 4 (20) 13 (65) 3 (15)
 T0 4 0 (0) 4 (100) 0 (0)
Postoperative N1
 N0 124 51 (41) 34 (27) 39 (32)
 N1 55 25 (46) 14 (25) 16 (29)
 N2 28 12 (43) 4 (14) 12 (43)
 Nx 3 0 (0) 0 (0) 3 (100)
Postoperative stage1
 Stage I 55 26 (47) 4 (7) 25 (46)
 Stage II 66 25 (38) 24 (36) 17 (26)
 Stage III 85 37 (44) 20 (23) 28 (33)
 No viable tumor left 4 0 (0) 4 (100) 0 (0)
Postoperative grade3
 G1 32 9 (28) 10 (31) 13 (41)
 G2 134 56 (42) 32 (24) 46 (34)
 G3 35 21 (60) 3 (9) 11 (31)
 Gx 9 2 (22) 7 (78) 0 (0)
Circumferential margin
 0 18 3 (17) 11 (61) 4 (22)
 0≤ crm ≤2 21 8 (38) 6 (29) 7 (33)
 >2 120 65 (54) 25 (21) 30 (25)
 Unknown 51 12 (23) 10 (20) 29 (57)
Disease- specific outcome
 Alive without recurrence 114 59 (52) 22 (19) 33 (29)
 Alive with recurrence 9 3 (33) 3 (33) 3 (33)
 Died of disease 56 16 (28) 20 (36) 20 (36)
 Died of other causes 31 10 (32) 7 (23) 14 (45)
1T, the extent of tumor invasion; N, nodal status, and stage according to the TNM classification of malignant tumors [16].
2Includes the T3 tumors with threatened circumferential margin involvement.
3Postoperative tumor differentiation grade.
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primary tumor (easy to find). In tumors with excellent 
response, very few or no tumor cells could be found.
Statistical analysis
Statistical analyses for rectal cancer dataset were run using 
IBM SPSS Statistics 22.0.0.1 for Windows (IBM 
Corporation, Somers, NY) software package. Frequency 
tables were analyzed using the c2- test, with the likelihood 
ratio (LR) or Fisher’s exact test for categorical variables. 
Contingency tables (2 × 2) were used to calculate odds 
ratio (OR) and 95% confidence interval (CI) using the 
exact method. Fisher’s exact test, Spearman’s correlation, 
and LR were used to assess the significance of the cor-
relation between individual variables in univariate analysis. 
Interobserver reproducibility of the assessments was tested 
with weighted kappa, calculated using the intraclass cor-
relation coefficient (ICC) test, in parallel mode with a 
two- way random model, using consistency assumption 
and the average- measures option to interpret the ICC 
(95% CI). The ICC of assessments was very good, with 
weighted kappa values around 0.8.
Univariate survival analysis for disease- free survival (DFS) 
and disease- specific survival (DSS) was based on the 
Kaplan–Meier method where stratum- specific outcomes 
were compared using log- rank (Mantel–Cox) statistics. To 
adjust for the covariates, a Cox proportional hazards re-
gression model was used. Covariates (as listed separately 
in results) were entered in a stepwise backward manner.
The TCGA colon and rectum adenocarcinoma 
(COADREAD) exon expression by RNAseq (Illumina HiSeq) 
dataset (n = 416) was downloaded from UCSC cancer genom-
ics browser, and analyzed by JMP Pro 11.1.1 (SAS Institute 
Inc., Cary, NC, USA) software. PPME1 expression distribution 
was studied and overall survival (OS) estimate curves were 
generated using Kaplan–Meier method (n = 396). Log- rank 
chi- square test was used to assess the significance of correla-
tion between variables. To study the significance of PPME1 
mRNA expression compared to covariate variables, Cox 
proportional hazards regression model was fitted for the 
COADREAD dataset. Model fitting was done in R version 
3.1.2 [20] using package “Survival v.2.37- 7” [21]. To make 
the results comparable, a set of covariates corresponding as 
closely to the clinical variables in the rectal cancer dataset 
as possible was aggregated from TCGA clinical data.
The statistical analyses of western blots was performed 
with MS excel using two- tailed Student’s paired t- test. 
All statistical tests were two- sided and declared significant 
at a P- value of <0.05.
Results
Validation of the specificity of PME- 1 
antibody in CRC cell lines
In order to confirm the specificity of PME- 1 antibody to 
be used for immunohistochemistry of patient tumor ma-
terial, we tested a PME- 1 antibody in colon cancer cell 
lines, HCA- 7, and CW- 2. PME- 1- specific siRNA was used 
to knockdown its expression in these cells, which were 
lysed and subjected to western blotting with PME- 1 (clone 
B- 12) mouse monoclonal antibody (Fig. 1A). This antibody 
Figure 1. Validation of the specificity of PME- 1 antibody in colorectal cancer cell lines. (A) Western blot image of protein lysates from HCA- 7 and CW- 2 
cells transfected with scrambled (S) or PME- 1 (P) siRNA (for 72 h), and blotted with PME- 1 (B- 12) antibody. GAPDH was used as a protein loading control. 
Black lines denote the location of protein molecular weight marker bands. Immunofluorescence images of HCA- 7 (B) and CW- 2 (C) cells transfected with 
Scr or PME- 1 siRNA (for 72 h), and incubated with PME- 1 antibody and visualized with anti- mouse- Alexa- 594 secondary antibody (red). Hoechst 33342 
shows nuclear staining (blue). PME- 1 and nuclear staining overlay is shown in merge (fuchsia). All images were taken at 40× magnification.
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recognized only one band corresponding to the molecular 
weight of PME- 1 (44 kDa) in the control (Scr. siRNA 
transfected) cells. The intensity of this band was greatly 
reduced in the cells transfected with PME- 1 siRNA, sug-
gesting that the antibody is specifically recognizing PME- 1 
in these cell lysates. We used the same approach to test 
the PME- 1 antibody specificity by immunofluorescence, 
which corroborated the western blotting results in both 
HCA- 7 (Fig. 1B) and CW- 2 (Fig. 1C) cells. PME- 1 stain-
ing was present evenly in both cytoplasm and the nucleus 
in CW- 2 cells; however, the HCA- 7 cells displayed more 
intense staining in the nucleus as compared to the cyto-
plasm (Fig. 1B).
PME1 protein expression in rectal cancer 
samples
As observed in the colon cancer cell lines, the PME- 1 
staining was localized both in the cytoplasm and nucleus, 
also in the sections made from paraffin blocks of clinical 
tumor samples. The staining intensity varied from one 
tumor to another, and the median of most intensive 
PME- 1 index concerning both cytoplasm and nucleus was 
1.2. Normal rectal epithelium was mostly negative, although 
in some samples there was faint background- like staining 
in some areas, especially in those near the cancer cells. 
Examples of negative, weak, moderate, and strong PME- 1 
expression by IHC are illustrated in Figure 2A.
PME- 1 protein expression related to 
clinicopathological variables
Among men, the most intensive cytoplasmic index of 
PME- 1 was more often below median than among women 
(P = 0.027, Pearson χ2 test). The recurrent disease was 
more common among patients with most intensive cy-
toplasmic index of PME- 1 below median than those above 
median (P = 0.003, Pearson χ2 test). The correlations of 
these clinicopathological variables and PME- 1 staining are 
shown in Table 2. There was no significant correlation 
between PME- 1 most intensive cytoplasmic staining index 
in relation to age, the nodal status, postoperative T, 
Figure 2. PME- 1 expression correlates with better survival of colorectal cancer patients. (A) Representative images of PME- 1 immunohistochemical 
staining from rectal carcinoma patient samples used for correlation analysis (scored 0–3). (B) Kaplan–Meier survival curve for disease- free survival (DFS) 
(in months) analysis by PME- 1 most intensive cytoplasmic staining index in rectal cancer patient cohort (n = 195). (C) Kaplan–Meier survival curve for 
overall survival (OS) (in days) by PPME1 gene expression (RNAseq exon array) in TCGA colon and rectal adenocarcinoma (COADREAD) patients 
(n = 396).
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postoperative stage, postoperative grade, circumferential 
margin, vascular invasion, or postradiotherapy (RT) TRG 
(Table S1).
PME- 1 expression is related to DFS of rectal 
cancer patients
In the univariate survival analyses for the whole cohort, 
tumors with the most intensive cytoplasmic index of PME- 1 
under median were linked to shorter DFS than those 
over median (110.7 vs. 116.7 months, P = 0.007, log- rank 
test; Fig. 2B).
The multivariate (Cox) proportional hazards regression 
for DFS was performed for the patients with following co-
variates: treatment group, sex, age (70 years as cutoff), post-
operative N (positive/negative), vascular invasion (positive/
negative), circumferential margin (2 mm as cutoff), and the 
most intensive cytoplasmic index of PME- 1 (median as cut-
off). The following remained as independent factors predicting 
a poor DFS of rectal cancer patients: sex if male (hazard 
ratio [HR] 4.12; 95% CI 0.25–0.98; P = 0.042), postoperative 
N (HR 10.33; 95% CI 1.68–8.40; P = 0.001), circumferential 
margin (HR 6.13; 95% CI 1.19–4.53; P = 0.013), and the 
most intensive cytoplasmic index of PME- 1 (HR 9.28; 95% 
CI 1.78–14.31; P = 0.002). The multivariate (Cox) 
Table 2. Association of clinicopathological variables of rectal cancer 
 patients with PME- 1 protein expression (most intensive cytoplasmic 
index).
Variable
Total 
n = 1951
PME- 1 most intensive 
cytoplasmic index
P- value2
Below median, 
n (%)
Above median, 
n (%)
Sex
 Female 85 53 (62) 32 (38) 0.027
 Male 110 85 (77) 25 (23)
Recurrence
 Yes 57 49 (86) 8 (14) 0.003
 No 138 89 (64) 49 (36)
1PME- 1 most intensive cytoplasmic staining index could be analyzed 
from 195 patients only.
2Pearson chi- square test.
Table 3. Multivariate survival analysis of rectal cancer patient samples and TCGA colon and rectal adenocarcinoma (COADREAD) patient samples 
using Cox proportional hazards regression models.
Variables
Rectal cancer (n = 142)1
Disease- free survival
Rectal cancer (n = 114)1
Disease- specific survival
TCGA COADREAD (n = 347)1
Overall survival
HR 95% CI P- value HR 95% CI P- value HR 95% CI P- value
Sex
 Female 1 1 1
 Male 4.12 0.25–0.98 0.042 0.34 0.39–1.66 0.560 1.68 1.01–2.79 0.046
Age
 ≤70 years 1 1 1
 >70 years 1.38 0.32–1.33 0.240 4.46 0.24–0.95 0.035 1.91 1.16–3.16 0.011
Circumferential margin
 ≤2 mm 1 1
 >2 mm 6.13 1.19–4.53 0.013 1.63 0.78–3.20 0.201
Postoperative N2
 Negative (N0) 1 1 1
 Positive (N1- 2) 10.33 1.68–8.40 0.001 0.79 0.54–4.99 0.374 3.15 1.79–5.53 <0.001
Vascular invasion3
 Negative 1 1 1
 Positive 1.93 0.82–3.16 0.165 0.42 0.36–1.66 0.519 1.47 0.86–2.48 0.162
Disease recurrence
 No 1
 Yes 21.62 15.50–840.54 <0.001
PME- 1 expression4,5
 High 1 1 1
 Low 9.28 1.78–14.31 0.0024 0.1 2.75–2.53 0.7514 2.22 1.32–3.72 0.0025
HR, hazard ratio; 95% CI, 95% confidence interval. Statistically significant P-values are indicated in bold.
1Only 142 and 114 Rectal cancer patients for disease- free survival and disease- specific survival, respectively, and 347 TCGA COADREAD patients for 
overall survival could be analyzed for which complete data were available for all the covariates.
2Postoperative nodal status according to the TNM classification of malignant tumors [16].
3For TCGA data, vascular invasion indicates combined lymphatic, and/or venous invasion status.
4PME- 1 most intensive cytoplasmic index (protein expression) measured by IHC (cut- off median).
5PPME1 mRNA expression measured by RNA sequencing exon array Illumina HiSeq (cutoff −0.075).
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proportional hazards regression for DSS was performed for 
patients with the similar covariates as that for DFS added 
with disease recurrence. The following remained as inde-
pendent factors predicting a poor DSS: age if over 70 years 
(HR 4.46; 95% CI 0.24–0.95; P = 0.035) and disease recur-
rence (HR 21.62; 95% CI 15.50–840.54; P < 0.001). The 
multivariate (Cox) proportional hazards regression results 
for DFS and DSS have been presented in Table 3.
PME- 1 gene expression correlates with OS of 
CRC patients
In an independent colon and rectum adenocarcinoma 
(COADREAD, n = 396) RNA sequencing dataset (exon 
array IlluminaHiSeq) available from TCGA [22], we ana-
lyzed the correlation between OS and PPME1 gene ex-
pression using UCSC Cancer Genomics Browser [23, 24]. 
Although the PPME1 expression was normally distributed 
among this dataset, two distinct groups can be clearly 
isolated using cut- off value of −0.075 (Figure S1A). Based 
on this cut- off value, the data were categorized into two 
groups, low PPME1 (expression below −0.075) and high 
PPME1 (expression above −0.075) (Fig. 2C). This analysis 
revealed a similar trend at the mRNA expression level as 
was seen for PME- 1 protein expression in our rectal cancer 
dataset. The patient group with high PPME1 gene expres-
sion (n = 249) showed better OS (P = 0.005 log- rank 
χ2 test) than the patients with low PPME1 expression 
(n = 147). Similar results were seen using median PPME1 
expression (0.07014) as a cutoff (Fig. 1B and C).
The multivariate analysis of TCGA COADREAD panel 
was performed by Cox proportional hazards regression 
models to assess the effect of other possible variables 
contributing to the prognosis of CRC patients in the 
Kaplan–Meier survival analysis. This analysis was carried 
out in 347 patients, for which full data was available for 
the following covariates: sex, age (cutoff 70 years), patho-
logic N (positive/negative), vascular invasion (positive/
negative), and PPME1 gene expression (cutoff −0.075). 
This analysis revealed low PPME1 expression as an in-
dependent high- risk factor (HR 2.22; 95% CI 1.32–3.72; 
P=0.002) predicting poor OS of CRC patients. Additionally, 
male gender (HR 1.68; 95% CI 1.01–2.79; P = 0.046), 
high age (>70 years) (HR 1.91; 95% CI 1.16–3.16; 
Figure 3. Modulation of survival signaling by PME- 1 in colorectal cancer cells. The viability of HCA- 7 and CW- 2 cells transfected with Scr. or PME- 1 
siRNA (for 72 h) was analyzed by CellTiter- glo (CTG) (A) and WST- 1 (B) assays. Bars represent fold- change values calculated over respective values for 
Scr. siRNA- transfected cells (n = 3). Western blot analysis of protein lysates from siRNA- transfected HCA- 7 (C) and CW- 2 (D) cells, using antibodies to 
phosphorylated forms of AKT and ERK. The phosphoprotein expression normalized with GAPDH (loading control) is shown as fold- change values over 
Scr. siRNA- transfected cells (n = 3). *P = 0.003 by Student’s paired t- test.
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P = 0.011), and pathologic N positivity (HR 3.15; 95% 
CI 1.79–5.53; P < 0.001) were significant risk factors 
predicting poor OS of CRC patients. These results have 
been presented in Table 3. The multivariate analysis for 
TCGA COADREAD panel carried out using above men-
tioned covariates and median PME- 1 expression as cutoff 
also showed similar results (Table S2).
Modulation of survival signaling by PME- 1 
in CRC cells
PME- 1 silencing has been shown to inhibit viability and 
reduce the phosphorylated AKT and ERK levels in the 
glioblastoma cells [9] as well as in PME- 1 amplified gastric 
and lung cancer cells [14]. To study the alterations in 
survival signaling by PME- 1 in colon cancer, PME- 1 
specific siRNA was employed to knockdown its expres-
sion and the viability was analyzed in CW- 2 and HCA- 7 
cell lines. Neither of the cell lines displayed significant 
difference in viability upon PME- 1 silencing, confirmed 
by using two different cell viability assays (Fig. 3A and 
B). Further immunoblotting analysis revealed that in 
contrast to other cancer types, PME- 1 silencing did not 
inhibit expression of active phosphorylated forms of ser-
ine–threonine- specific protein kinases AKT- 1/2/3 (p- AKT) 
and ERK- 1/2 (p- ERK) in either of the colon cancer cell 
lines (Fig. 3C and D). In fact, the expression of p- AKT 
in HCA- 7 cells was significantly higher (twofold, 
P = 0.003) in PME- 1 silenced cells as compared to the 
control (Scr. siRNA) cells (Fig. 3C); and even though 
the other effects did not reach the statistical significance, 
there was a clear trend toward higher p- AKT also in 
CW- 2 cells and higher p- ERK in both the cells lines 
upon PME- 1 inhibition. These findings demonstrate that 
opposite to other caner types PME- 1 may even decrease 
survival signaling in CRC cells and this may be linked 
to better patient outcome of rectal cancer patients with 
higher PME- 1 expression.
Discussion
PME- 1 expression on protein level was studied in 195 
rectal cancer patients. Among these patients, 52 were 
treated with long- course (chemo) RT, 88 with short- course 
RT, and 70 with surgery only. Our aim was to test PME- 1 
as a potential marker to predict the outcome of rectal 
cancer patients.
There is little information available concerning the role 
of PME- 1 for patient outcome in human malignancies. 
Based on its molecular function as a PP2A inhibitor pro-
tein such as CIP2A [8], it would be expected that PME- 1 
would also act as a human oncoprotein. It has been shown 
that PME- 1 is linked with the malignant progression of 
astrocytic gliomas [9] and endometrial cancers [13]. For 
this reason it is surprising that PME- 1 protein expression 
seems to act in an opposite way in rectal cancer. High 
protein expression of PME- 1 is a marker for favorable 
outcome in univariate analysis of DFS for the whole co-
hort, and it remained an independent prognosticator of 
DFS together with sex, postoperative N status, and cir-
cumferential margin. Importantly, tumors with high PME- 1 
protein expression were associated with fewer recurrences 
and a better disease outcome than those with low PME- 1 
protein expression. The importance of these findings was 
further highlighted by the observation that in addition 
to the rectal cancer, colon cancer patients from an in-
dependent cohort (COADREAD) could be categorized into 
two groups based on PPME1 mRNA expression, which 
correspond to differential OS outcome in both univariate 
and multivariate survival analyses. This information can 
be useful for establishing PCR tests based on PPME1 
expression as a biomarker to predict the survival of CRC 
patients [25, 26].
PME- 1 expression is known to be associated with 
increased cell proliferation and survival signaling in 
human malignant gliomas and endometrial cancers [9, 
13]. We studied these cellular functions in CRC cells. 
Since PP2A inhibition by PME- 1 has been previously 
shown to promote phosphorylation of the AKT and 
ERK proteins, it is surprising that in CRC cells these 
prosurvival signaling events are largely unaffected or 
affected in an opposite manner as compared to the 
other types of cancer. Mechanistically, PME- 1 promotes 
ERK pathway signaling mainly at a level upstream of 
Raf [9]. However, a significant proportion of the CRCs 
contain activating mutations in K- Ras (50%) and B- 
Raf (10%), which promote ERK signaling independent 
of the upstream stimuli [27]. In addition, the TGFα- 
mediated autocrine feedback loop can further increase 
the Ras- Raf- ERK pathway signaling [27, 28]. These 
alterations may render the CRC cells insensitive to 
PME- 1- mediated regulation. Furthermore, inactivating 
mutations and/or altered expression of various PP2A 
components [29, 30], specifically the B- subunits regu-
lated by PME- 1, might affect the activity (phosphoryla-
tion) of specific target proteins. To this end, among 
the PP2A B- subunits of PPP2R2 (B55) family, which 
are exclusively sensitive to PP2A C- subunit Leu309 
methylation reversibly removed by PME- 1 [31], the 
PPP2R2B (B55β) subunit is epigenetically silenced by 
DNA hypermethylation in >90% of CRCs [32]. The 
loss of this B- subunit promotes drug resistance in CRC 
by activating the survival signaling in a PI3K- AKT 
independent manner [32]. It may be speculated that 
our surprising result of a favorable outcome with high 
PME- 1 expression is related to these altered pathways 
1807© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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in CRC. Overall, the unexpected role for PME- 1 in 
CRCs is intriguing and calls for careful examination 
of cancer- specific function for each of the PP2A 
 inhibitor proteins when considering their role as 
 biomarkers and potential targets for future cancer 
therapies.
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